RGIN Projected Dividend Yield

Regenicin, Inc. ( OTCBB : RGIN )

Regenicin is engaged in developing and commercializing a technology by the introduction of tissue-engineered skin substitutes to restore healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. Co.'s cultured skin substitute product candidate, NovaDerm®, is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. Co.'s other product TempaDerm® uses cells obtained from human donors to develop banks of cryo-preserved (frozen) cells and cultured skin substitute to provide a continuous supply of non-allogenic skin substitutes to treat much smaller wound areas on patients, such as ulcers.

21 YEAR PERFORMANCE RESULTS